NCT04986748 is a clinical trial in Sarcoma, sponsored by National Cancer Centre, Singapore.

Who is sponsoring NCT04986748?

NCT04986748 is sponsored by National Cancer Centre, Singapore.

What condition does NCT04986748 study?

NCT04986748 studies Sarcoma, Melanoma.

Is NCT04986748 still recruiting?

NCT04986748 is currently recruiting now. Last updated 1 July 2025.

Last reviewed 2025-07-01 · How we verify

NCT04986748

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Using QPOP to Predict Treatment for Sarcomas and Melanomas

Recruiting now Last updated 1 July 2025

What this trial tests

trial in Sarcoma in 100 participants. Currently enrolling.

Timeline

8 September 2020

Primary endpoint
31 October 2028

31 December 2028

Quick facts

Lead sponsor	National Cancer Centre, Singapore
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	100
Start date	8 September 2020
Primary completion	31 October 2028
Estimated completion	31 December 2028
Sites	1 location across Singapore

Conditions studied

Sarcoma — all drugs for Sarcoma →
Melanoma — all drugs for Melanoma →

Sponsor

National Cancer Centre, Singapore

Who can join

Adults 21 to 99, any sex, with Sarcoma or Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multi-cohort proof of concept study involving patients with sarcomas or melanomas. Patient models, both two- and three-dimensional, will be derived from tumour samples. These will then be used to evaluate drug sensitivities ex vivo. Enrolled patients will undergo resections or biopsies as part of standard-of-care, which will be used to generate patient models. Patients will receive standard-of-care systemic treatment. Patient models will also be subjected up to a 14-drug screening panel. The majority of drugs in the respective drug panels has been shown to have activity in the respective cancers and would be used in the standard-of-care setting by treating physicians.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology.
Thorel L, Perréard M, Florent R, Divoux J, et al · · 2024 · cited 90× · PMID 38945959 · DOI 10.1038/s12276-024-01272-5
Organoids: development and applications in disease models, drug discovery, precision medicine, and regenerative medicine.
Yao Q, Cheng S, Pan Q, Yu J, et al · · 2024 · cited 40× · PMID 39309690 · DOI 10.1002/mco2.735
Opportunities and challenges for patient-derived models of brain tumors in functional precision medicine.
Mann B, Artz N, Darawsheh R, Kram DE, et al · · 2025 · cited 12× · PMID 39953052 · DOI 10.1038/s41698-025-00832-w
A functional personalised oncology approach against metastatic colorectal cancer in matched patient derived organoids.
Thng DKH, Hooi L, Siew BE, Lee KY, et al · · 2024 · cited 10× · PMID 38413740 · DOI 10.1038/s41698-024-00543-8
Functional precision medicine: the future of cancer care.
Acanda de la Rocha AM, Berlow NE, Azzam DJ. · · 2025 · cited 5× · PMID 39567286 · DOI 10.1016/j.molmed.2024.10.015
Combination of Genomic Landsscape and 3D Culture Functional Assays Bridges Sarcoma Phenotype to Target and Immunotherapy.
de Nigris F, Meo C, Palinski W. · · 2023 · cited 3× · PMID 37681936 · DOI 10.3390/cells12172204
The functional imperative in high-grade glioma.
Goh LSH, Thng DKH, Ang YLE, Ho D, et al · · 2026 · PMID 41501375 · DOI 10.1038/s12276-025-01614-x

Verify or expand the search:

Other recruiting trials for Sarcoma

Currently open trials in the same condition.

NCT07402577 — Brief Title Mechanisms of Cancer-Related Pain and Opioid Use Among Adolescents and Young Adult Sarcoma Survivors: Pilot · recruiting
NCT07501026 — Preoperative Spatially Fractionated Radiation Therapy (SFRT) in Soft Tissue Sarcoma (neoSFRT-SARC) · Phase 2 · recruiting
NCT07359911 — Effect of A Multimodal Exercise Intervention on Chemotherapy Uptake in Newly Diagnosed Pediatric and AYA Sarcoma Patient · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07222735 — Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcoma · Phase 1 · recruiting

Other National Cancer Centre, Singapore trials

Trials by the same sponsor.

NCT07428356 — Histotripsy for Ablation of Liver Tumours in Asia · NA · recruiting
NCT07428655 — Acceptability and Feasibility of PSC Model of Serious Illness Communication · NA · active not recruiting
NCT07116161 — Exercise Therapy and Cognitive Behavioural Therapy for Fatigue in Female Cancer Patients in Singapore · NA · recruiting
NCT06977360 — Feasibility, Acceptability and Preliminary Efficacy of the New Iteration of the Innovative Smartphone-based Care Solutio · NA · recruiting
NCT06766058 — Evaluating the Effectiveness of Aromatherapy for Alleviating Distress in Breast Cancer Patients Before Radiotherapy. · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04986748 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cancer Centre, Singapore
Last refreshed: 1 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04986748.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing